Brought to you by 
Pacira nets $63.2mm in follow-on public offering
25 Apr 2012
Executive Summary
A follow-on public offering of 6.9mm shares (including the overallotment) netted Pacira Pharmaceuticals Inc. (applies DepoFoam extended-release drug delivery technology to acute care products) $63.2mm. The stock was sold at $9.75 apiece. Proceeds will go towards manufacturing and marketing of Exparel (liposomal bupivacaine), approved late last year for postsurgical anesthesia, and for efforts to expand the indication of the drug to include nerve block.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Controlled Release
-
Drug Delivery
-
Biotechnology
- Liposomes
Deal Status
- Final
Deal Type
-
Financing
- FOPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pacira nets $63.2mm in follow-on public offering
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice